PolyPeptide Group The peptide CDMO (Contract Development and Manufacturing Organization) sector is experiencing significant growth, marked by increasing market valuations, strategic investments, and notable industry news. Recent developments highlight a dynamic landscape where companies are expanding capabilities, forging collaborations, and responding to the escalating demand for peptide-based therapeutics. The global peptide and oligonucleotide CDMO market, projected to reach substantial figures by the end of the decade, underscores the sector's robust upward trajectory.
The peptide CDMO market is a burgeoning segment within the pharmaceutical industry, driven by the expanding pipeline of peptide therapeutics and the increasing complexity of their manufacturing. Projections indicate a sustained period of growth, with market size forecasts consistently pointing towards significant expansion. For instance, the global peptide and oligonucleotide CDMO market was valued at approximately USD 2.Peptide and Oligonucleotide CDMO Market | Industry ...80 billion in 2024 and is anticipated to reach USD 8Lifecore and PolyPeptide Announce Collaboration ....14 billion by 2033, reflecting a compound annual growth rate (CAGR) of over 12%Peptide and Oligonucleotide CDMO Market Size. Similarly, other reports suggest the market was valued at USD 2CordenPharma Builds >€500m Switzerland Peptide ....3 billion in 2023 and is expected to grow at a CAGR exceeding 12.2026年1月19日—ThePeptideAnd OligonucleotideCDMOMarket worth USD 2.98 billion in 2026 is growing at a CAGR of 11.05% to reach USD 5.03 billion by 2031.1% from 2024 to 2032.GLP-1 Peptide Synthesis CDMO Market Size, Share and ... These figures demonstrate a strong consensus on the sector's impressive expansion potentialpeptide-focused CRDMO.
The demand for specialized services, particularly in areas like GLP-1 peptide synthesis, further fuels this growth. The GLP-1 peptide synthesis CDMO market, for example, is predicted to grow at a CAGR of 12.7% between 2025 and 2034. This surge is attributable to increasing research and development in biologics, the formation of strategic partnerships, and continuous innovation within the field of peptide therapeutics.2025年10月28日—PolyPeptide is a specializedCDMOforpeptide-based active pharmaceutical ingredients. PolyPeptide serves a fast growing market, and is a ...
Recent peptide CDMO news is characterized by significant corporate activities, including expansions, acquisitions, and strategic investments aimed at bolstering manufacturing capabilities and market presence.
* Facility Expansions and Investments: Companies are making substantial capital commitments to scale up their peptide manufacturing operations. CordenPharma, for instance, announced a significant investment of over €500 million to construct a new peptide manufacturing facility near Basel, Switzerland, focusing on expanding its GLP-1 peptide platformPeptide CDMO Pharmaceutical Market Analysis 2026. SK pharmteco is also making strategic investments, including a $6.1 million expansion at its California facility to enhance its peptide development and CGMP (Current Good Manufacturing Practice) kilo-scale capabilities, and a broader investment to boost domestic peptide scale-up.
* Mergers and Acquisitions: The consolidation trend within the industry is evident through acquisitionsPeptide CDMO Pharmaceutical Market Analysis 2026. Granules India has agreed to acquire Senn Chemicals, a Swiss-based CDMO specializing in peptides, further integrating capabilities and market reach.
* Collaborations and Partnerships: Strategic collaborations are crucial for advancing technology and market access. Eurofins CDMO Alphora is participating in an international consortium project focused on developing a high-yield expression platform for next-generation antibody-drug conjugates (ADCs), integrating optimized affinity peptide tags2024年7月16日—CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years togrow its Peptide technology.... HLB Pep has also signed a Memorandum of Understanding (MOU) with YMC Korea to enhance efficiency and quality in peptide active pharmaceutical ingredient (API) manufacturing. PolyPeptide Group AG, a specialized CDMO for peptide-based APIs, continues to announce strategic collaborations and partnerships, reflecting its active role in the marketEurofins CDMO Alphora Joins International Consortium ....
Several companies are consistently featured in peptide CDMO news, highlighting their significant contributions and market leadershipHLB Pep Signs MOU with YMC Korea to Strengthen High .... PolyPeptide Group, SK pharmteco, CordenPharma, and Eurofins CDMO Alphora are frequently mentioned for their expansions, investments, and strategic initiativesPeptide and Oligonucleotide CDMO Market | Industry .... AmbioPharm is also recognized as a growing global peptide CDMO20小时前—CRDMO sales dip 19% but stronger gross margin lifts EBITDA margin to 37.1%. Firm eyes mid-teen FY26 growth, peptide, ....
Emerging trends include a heightened focus on specialized peptide synthesis, such as for GLP-1 agonists, and advancements in manufacturing technologies. The development of novel expression platforms and the integration of peptide technologies into broader therapeutic modalities like ADCs are also shaping the industry's future. The increasing demand for high-quality peptide APIs underscores the critical role of CDMOs in bringing innovative peptide-based drugs to market efficiently and reliably.2025年7月10日—Global Peptide CDMO Services market was valued at USD 3867M in 2024and is projected to reach USD 10800M by 2032, at a CAGR of 16.2%. The overall outlook for the peptide CDMO sector remains exceptionally positive, driven by ongoing innovation and substantial market growth.
Join the newsletter to receive news, updates, new products and freebies in your inbox.